In:
International Journal of Molecular Sciences, MDPI AG, Vol. 21, No. 3 ( 2020-01-21), p. 708-
Abstract:
Bone marrow mesenchymal stem/stromal cells (BMSCs), which are known as multipotent cells, are widely used in the treatment of various diseases via their self-renewable, differentiation, and immunomodulatory properties. In-vitro and in-vivo studies have supported the understanding mechanisms, safety, and efficacy of BMSCs therapy in clinical applications. The number of clinical trials in phase I/II is accelerating; however, they are limited in the size of subjects, regulations, and standards for the preparation and transportation and administration of BMSCs, leading to inconsistency in the input and outcome of the therapy. Based on the International Society for Cellular Therapy guidelines, the characterization, isolation, cultivation, differentiation, and applications can be optimized and standardized, which are compliant with good manufacturing practice requirements to produce clinical-grade preparation of BMSCs. This review highlights and updates on the progress of production, as well as provides further challenges in the studies of BMSCs, for the approval of BMSCs widely in clinical application.
Type of Medium:
Online Resource
ISSN:
1422-0067
DOI:
10.3390/ijms21030708
Language:
English
Publisher:
MDPI AG
Publication Date:
2020
detail.hit.zdb_id:
2019364-6
SSG:
12
Permalink
